Diferencias de sexo en la eficacia, seguridad y persistencia de los pacientes con artritis psoriásica tratados con tofacitinib: Un análisis post hoc de ensayos de fase 3 y extensión a largo plazo
RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718
Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.